Drugs / Black raspberry
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06086925 | Jun 2025 → Jun 2027 | head and neck squamous cell carcinoma | Mitchell Machtay | Withdrawn | No outcome recorded Stop: Business |
| Phase 12 trials | ||||||
| Phase 1 | NCT02267694 | Aug 2013 → Oct 2015 | ulcerative colitis | UConn Health | Completed | No outcome recorded |
| Phase 1 | NCT00770991 | Dec 2005 → Sep 2008 | classic or attenuated familial adenomatous polyposis | The Cleveland Clinic | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Black raspberry | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00770991 ↗ |
| Known as | blackcaps | “Black Raspberries (BRB), also referred to as "blackcaps", are an entirely natural resource available over-the-counter for purchase.” NCT06086925 ↗ |
| Known as | BRB | “Black raspberry (BRB) Slurry” NCT00770991 ↗ |
| Route | Rectal | “Two, 730 mg BRB suppositories QHS” NCT00770991 ↗ |